The scientists at the University of California, San Francisco and Johns Hopkins University in Baltimore injected an antisense ...

A new study has found that spending too much time sitting down could increase your risk of dementia, no matter how often you ...

In a comprehensive Genomic Press Commentary published today, researchers have identified what could be the first reliable biomarker for depression risk, potentially transforming how this devastating ...

A woman who passed away as a result of being diagnosed with PCA didn't necessarily show 'tell-tale signs,' with her family ...

Hypertension and other health risks accelerate brain aging, as shown in a 16-year study using MRI data and predictive ...

ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity ...